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Abstract
Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver worldwide. The
incidence of HCC is increasing in North America secondary to rises in chronic liver disease from
alcohol abuse and viral hepatitis. HCC most commonly metastasizes hematogenously or through
lymphatics to the lungs and regional lymph nodes. Involvement of small bowel is rare and typically
results from direct invasion and extension. We examined the molecular features related to this
extremely rare case of isolated duodenal metastasis of HCC and noted p53 and Ki-67 positive
staining. Here, we review the possible molecular and immunohistochemical studies that may aid
definitive diagnosis and the evidence for the management of metastatic hepatocellular carcinoma.
Background
Hepatocellular carcinoma (HCC) is the 6th most com-
mon cancer and the 3rd most common cause of cancer
death worldwide [1]. It is most common in Asia and
Africa; however the incidence of HCC in North America is
rising, mostly related to cirrhosis from hepatitis C infec-
tion or alcohol abuse.
HCC most commonly metastasizes via blood vessels or
lymphatics to the regional lymph nodes, lungs and bone.
Other less common sites of spread that have been
reported include the adrenal gland, stomach, peritoneum,
kidney, spleen, heart, and brain. Metastasis to the small
bowel is rare and the few cases of small bowel involve-
ment have been reported only as case reports or case
series. In most of the reported cases, small bowel involve-
ment was located at the proximal duodenum as a result of
direct extension from the primary tumor [2-6]. Hematog-
enous or lymphatic metastasis to the small bowel is
incredibly rare.
The patient discussed in this case report presented with an
upper gastrointestinal bleed secondary to HCC metastases
located at the distal duodenum, which to our knowledge,
has been reported only once previously[7] Here, we
describe this rare condition, the challenges involved in
clinical management, and the potential molecular mark-
ers associated with their aggressive behavior and poor
clinical outcomes.
Case presentation
This 53-year-old Canadian First Nations woman pre-
sented to emergency with abdominal pain, chest discom-
fort and melena. Her medical history included chronic
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hepatitis C, previous heavy alcohol consumption, cirrho-
sis and a recent diagnosis of multifocal hepatocellular car-
cinoma. Her other comorbid illnesses included type 2
diabetes mellitus, atrial fibrillation and valvular heart dis-
ease. At the time of initial diagnosis of HCC, a CT scan
demonstrated multiple hepatic lesions and portal vein
thrombosis. Although there was no evidence of tumor
extension beyond the liver, her underlying heart disease
and the presence of portal vein thrombosis deemed her an
ineligible candidate for either surgical resection or transar-
terial chemoembolization. Since her diagnosis of HCC,
she had been managed with long acting octreotide (San-
dostatin, Novartis Canada, Dorval QC) 20 mg intramus-
cularly given monthly for seven months when she
presented with abdominal discomfort and melena.
At presentation, she was hemodynamically stable and the
physical examination was unremarkable apart from the
presence of melena stool. Laboratory investigations
showed hemoglobin 85 g/L, with MCV of 71.7 fl, and a
normal serum AFP.
Esophagogastroduodenoscopy (EGD) revealed two
lesions in the third part of the duodenum: (i) a 2.5 cm soft
nodule resembling the liver parenchyma with a dark red
colour and hyperemic base, initially covered with a large
clot (ii) a larger ulcerated lesion located distal to the first
nodule, which was also covered in clot and more difficult
to visualize (Figure 1). These lesions were not actively
bleeding at the time of endoscopy, but the larger ulcerated
lesion with overlying clot was injected with epinephrine
to prevent further hemorrhage. There were no other obvi-
ous sources of bleeding and no identifiable esophageal or
gastric varices. An EGD was repeated 48 hours later to
reassess the duodenal lesions and multiple biopsies were
taken at this repeat endoscopy. A repeat CT scan of the
abdomen again revealed multifocal HCC and portal vein
thrombosis, as seen at diagnosis, but no evidence of local
invasion or extension into the duodenum.
Pathological findings
The biopsy fragments showed a moderately differentiated
carcinoma growing in a sheet-like fashion with an indis-
tinct sinusoidal pattern. The tumor cells had abundant
pale pinkish or clear cytoplasm and vesicular nuclei with
prominent nucleoli (Figure 2). Mucin production and bile
secretion were both absent. Low-grade cytologic pleomor-
phism was present but there were only occasional mitotic
figures. The histological appearances were considered typ-
ical for a moderately-differentiated hepatocellular carci-
noma. Immunostaining was carried out and positive
results were obtained for Heppar 1 (hepatocyte paraffin 1)
(Figure 3) and interestingly, α-fetoprotein (AFP), con-
firming the diagnosis of metastatic hepatocellular carci-
noma.
Ki-67 immunohistochemical staining was performed to
assess proliferative activity in the tumor. One thousand
cells were counted and 100 cells (10%) were positive. The
expression of a tumor suppressor, p53, was also assessed.
Twenty four percent of cell nuclei were either lightly or
heavily stained.
Discussion
Hematogenous metastasis to the duodenum from any pri-
mary malignancy is generally uncommon. Hematogenous
metastasis from HCC to the duodenum is exceedingly
Endoscopic photograph of metastatic lesions in duodenum at  the end of arrows 1 and 2 Figure 1
Endoscopic photograph of metastatic lesions in duo-
denum at the end of arrows 1 and 2.
Endoscopic biopsy specimen of duodenal lesion stained with  hematoxylin and eosin Figure 2
Endoscopic biopsy specimen of duodenal lesion 
stained with hematoxylin and eosin. The tissue has a 
sinusoidal arrangement of cells with large nuclei containing 
prominent nucleoli and eosinophilic cytoplasm. Low-grade 
nuclear pleomorphism is present (magnification × 200).Cases Journal 2009, 2:9344 http://www.casesjournal.com/content/2/1/9344
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rare. There have been several primary tumors with
reported hematogenous metastases to the duodenum
including carcinomas of the lung, breast, and malignant
melanoma [8-10]. In these cases, regardless of the primary
malignancy, diffuse and multiple metastases to several
visceral sites (particularly lung and liver) were present
when a duodenal metastasis was found, such that the duo-
denal involvement was of little clinical significance in the
overall management. Isolated duodenal metastasis from
HCC, as described in this case, has only been published
once before. This rare presentation posed both a diagnos-
tic and management challenge.
In this patient with known multifocal HCC, duodenal
lesions resembling liver parenchyma were found endo-
scopically, raising the suspicion that these lesions were
metastatic deposits of HCC. The majority of cases of duo-
denal involvement with HCC are a result of local exten-
sion of the primary tumour, but the CT scan demonstrated
no local invasion into the small bowel [2,5,6]. If these
lesions were considered metastatic deposits resulting from
hematogenous spread to the duodenum, extrapolating
from the available literature of other primary cancers, this
would present in the setting of widespread metastatic dis-
ease [8-10]. However, there was no distant metastatic dis-
ease noted on the staging CT scan, particularly in the
common sites of distant metastases: lung and bone.
In the setting of an unclear clinical presentation and small
biopsy specimens, it is often necessary to confirm the his-
tologic diagnosis using molecular and immunohisto-
chemical studies. This is particularly true for
endoscopically obtained biopsies, which are frequently
small and often damaged with crush injury. Immunos-
taining of the biopsy fragments for Heppar 1 and AFP may
help to resolve the histologic diagnosis of HCC. Heppar 1
immunostaining is present in 86% of hepatocellular car-
cinomas [11]. However, staining may also be present in
30-50% of gastrointestinal adenocarcinomas. Other intra-
abdominal neoplasms may have similar histologic
appearances to HCC with a sinusoidal growth pattern and
possibly clear cell differentiation. For example renal cell
carcinoma is generally negative for Heppar 1 staining
[12]. Alpha-fetoprotein immunopositivity is encountered
in only 37% of hepatocellular carcinomas but this is a
more specific immunostain [13]. Adenocarcinomas aris-
ing from the lung and gastrointestinal tract are almost
invariably AFP negative. The only other major class of
neoplasms that are AFP positive is germ cell tumors, espe-
cially endodermal sinus tumors. These are usually histo-
logically distinct and unlikely to be confused with a
hepatocellular carcinoma. In our case, the combination of
clinical knowledge of a multifocal primary HCC together
with positive Heppar1 and AFP staining conferred the
diagnosis of metastatic HCC to the small bowel.
The presence of high levels of p53 and Ki-67 expression in
this case correlates with a more aggressive tumor pheno-
type. Positive p53 and Ki-67 markers (positive staining in
>10% cells), in addition to high serum AFP levels, have
been suggested as predictors of poor clinical outcomes
and earlier recurrence of HCC [14]. Our findings support
previous reports of these more aggressive HCC pheno-
types that have metastasized to the small bowel.
With regards to treatment options, there is somewhat lim-
ited evidence to guide our management approaches, par-
ticularly for advanced tumour stages. Attempted
treatments in the advanced setting include chemoemboli-
sation, arterial or systemic chemotherapy, I131 lipiodol,
hormonal therapy, immunotherapy, and octreotide.
Meta-analysis of the randomized trials comparing chem-
oembolisation with conservative management has shown
a survival benefit with chemoembolisation. The chemo-
therapy agents previously tested for chemoembolisation
include doxorubicin and cisplatin. On the other hand,
meta-analysis of tamoxifen compared with conservative
management failed to show a survival benefit [15]. A
number of chemotherapy regimens have also been evalu-
ated in the palliative setting with no particular single
agent or combination chemotherapy regimen found to be
particularly effective or superior.
In this case, the patient's management was somewhat lim-
ited by the presence of portal vein thrombosis, which
made her ineligible for chemoembolization, and her
other medical comorbidities, which would pose signifi-
cant risk with more aggressive treatment. Given the avail-
able evidence around palliative single agent
Immunostain of the duodenal tumor showing diffuse cyto- plasmic heppar 1 positivity Figure 3
Immunostain of the duodenal tumor showing diffuse 
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chemotherapy, she was treated with six cycles of doxoru-
bicin every three weeks at disease progression. She sur-
vived another seven months on this regimen. It is difficult
to know whether this treatment extended her survival in
light of her extremely rare presentation of isolated duode-
nal metastasis.
Conclusions
This is the second reported case of isolated duodenal
metastasis of HCC without evidence of direct invasion or
widespread disseminated metastases. Given this rare pres-
entation, the diagnostic challenges were reviewed with
descriptions of possible molecular and immunohisto-
chemical studies that may help establish a definitive diag-
nosis. A brief review of the evidence for various treatment
options in the setting of metastatic HCC was also pre-
sented, which supported the management of this particu-
lar patient. This case demonstrates the variability in
presentation of metastatic HCC but also emphasizes the
need for further tools to improve diagnosis and treatment
of metastatic hepatocellular carcinoma.
Abbreviations
AFP: alpha fetoprotein; CT: computed tomography; EGD:
esophagogastroduodenoscopy; HCC: Hepatocellular car-
cinoma; VEGF: Vascular endothelial growth factor.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
CC and JAA collected the information and wrote the case
history of manuscript. CC finalized and submitted the
manuscript. DO collected the pathological information
and contributed to the pathological component of the
case history and discussion of the manuscript. AW con-
tributed to the endoscopic photos for the case history.
EMY and IT contributed to the discussion and edited the
final version of the manuscript. All authors read and
approved the final manuscript.
References
1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics.  CA
Cancer J Clin 2005, 55(2):74-108.
2. Chen LT, Chen CY, Jan CM, Wang WM, Lan TS, Hsieh MY, Liu GC:
Gastrointestinal tract involvement in hepatocellular carci-
noma: clinical, radiological and endoscopic studies.  Endoscopy
1990, 22(3):118-123.
3. Del Natale M, Druez P, Brenard R: Images in hepatology. Fistuli-
zation of a hepatocellular carcinoma into the duodenum.  J
Hepatol 2001, 34(1):172.
4. Hatano E, Ikai I, Shimizu M, Maetani Y, Konda Y, Chiba T, Terajima H,
Yamamoto N, Yamamoto Y, Shimahara Y, Yamaoka Y: Resection
for hepatocellular carcinoma with duodenal invasion: report
of a case.  Hepatogastroenterology 2003, 50(52):1034-1036.
5. Lin CP, Cheng JS, Lai KH, Lo GH, Hsu PI, Chan HH, Hsu JH, Wang
YY, Pan HB, Tseng HH: Gastrointestinal metastasis in hepato-
cellular carcinoma: radiological and endoscopic studies of 11
cases.  J Gastroenterol Hepatol 2000, 15(5):536-541.
6. Mohamed AO, Joshi S, Czechowski J, Branicki F: Hepatocellular
carcinoma directly invading the duodenum.  Saudi Medical Jour-
nal 2005, 26(3):478-480.
7. Humbert P, Sarmiento J, Boix J, Planas R, Quintero E, Franquet T, Vil-
lagrasa M: Hepatocellular carcinoma presenting with bleeding
due to duodenal perforation by the tumor.  Endoscopy 1987,
19(1):37-38.
8. Bender GN, Maglinte DD, McLarney JH, Rex D, Kelvin FM: Malig-
nant melanoma: patterns of metastasis to the small bowel,
reliability of imaging studies, and clinical relevance.  Am J Gas-
troenterol 2001, 96(8):2392-2400.
9. Hashimoto M, Miura Y, Matsuda M, Watanabe G: Concomitant
duodenal and pancreatic metastases from renal cell carci-
noma: report of a case.  Surg Today 2001, 31(2):180-183.
10. Houghton AD, Pheils P: Isolated duodenal metastasis from
breast carcinoma.  Eur J Surg Oncol 1987, 13(4):367-369.
11. Lugli A, Tornillo L, Mirlacher M, Bundi M, Sauter G, Terracciano LM:
Hepatocyte paraffin 1 expression in human normal and neo-
plastic tissues: tissue microarray analysis on 3,940 tissue
samples.  Am J Clin Pathol 2004, 122(5):721-727.
12. Fan Z, Rijn M van de, Montgomery K, Rouse RV: Hep par 1 anti-
body stain for the differential diagnosis of hepatocellular car-
cinoma: 676 tumors tested using tissue microarrays and
conventional tissue sections.  Mod Pathol 2003, 16(2):137-144.
13. Torbenson M, Kannangai R, Abraham S, Sahin F, Choti M, Wang J:
Concurrent evaluation of p53, beta-catenin, and alpha-feto-
protein expression in human hepatocellular carcinoma.  Am J
Clin Pathol 2004, 122(3):377-382.
14. Guzman G, Alagiozian-Angelova V, Layden-Almer JE, Layden TJ, Testa
G, Benedetti E, Kajdacsy-Balla A, Cotler SJ: p53, Ki-67, and serum
alpha feto-protein as predictors of hepatocellular carcinoma
recurrence in liver transplant patients.  Mod Pathol 2005,
18(11):1498-1503.
15. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma.  Lan-
cet 2003, 362(9399):1907-1917.